Cargando…

P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY

Detalles Bibliográficos
Autores principales:	Van Der Wagen, L., van Dorp, S., Bellido Cassado, M., Verheij, F., Nijssen, K., van der Velden, W., Biswana, A., Blijlevens, N., Kuball, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429622/ http://dx.doi.org/10.1097/01.HS9.0000848388.99548.61

Ejemplares similares

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Graft engineering: how long can you wait, how low can you go, and pandemic readiness
por: Nijssen, Klaartje, et al.
Publicado: (2023)

Fungal Planet description sheets: 1284–1382
por: Crous, P.W., et al.
Publicado: (2021)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS
por: Kok, Laurence M. C., et al.
Publicado: (2019)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation
por: Litjens, Nicolle H. R., et al.
Publicado: (2018)

Host Impairments in Patients with Neoplastic Diseases
por: Donnelly, J. Peter, et al.
Publicado: (2014)

Abstract 1382: Visualization and functional annotation of coronavirus spike protein glycoshields
por: Hsu, Shang-Te Danny, et al.
Publicado: (2023)

P1530: CORTICOSTEROIDS FOR INFLAMMATORY RESPONSES DURING INDUCTION CHEMOTHERAPY IN MYELOID MALIGNANCIES ARE NOT ASSOCIATED WITH INCREASED INCIDENCE OF INVASIVE FUNGAL INFECTIONS
por: Migchelbrink, Jorne, et al.
Publicado: (2023)

Decreased Levels of Circulating IL17-Producing CD161(+)CCR6(+) T Cells Are Associated with Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation
por: van der Waart, Anniek B., et al.
Publicado: (2012)

1382. Acute Kidney Injury with Piperacillin–tazobactam and Vancomycin in the Intensive Care Unit
por: Smith, Tameka, et al.
Publicado: (2018)

1382. The Lesser Known Treponemal Infections: A Review Of Non-Syphilitic Cases
por: Gupta, Ashima, et al.
Publicado: (2023)

Antibiotic prescribing in relation to diagnoses and consultation rates in Belgium, the Netherlands and Sweden: use of European quality indicators
por: Tyrstrup, Mia, et al.
Publicado: (2017)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

1382. Varicella Burden Disease in Argentina: 4 Years after National Vaccination Strategy
por: Neyro, Silvina, et al.
Publicado: (2020)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
por: Bonig, Halvard, et al.
Publicado: (2023)

Clinical versus histological grading in the assessment of cutaneous graft versus host disease
por: Hogenes, M. C. H., et al.
Publicado: (2019)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust
por: de Witte, Moniek, et al.
Publicado: (2021)

Ten years of health workforce planning in the Netherlands: a tentative evaluation of GP planning as an example
por: Van Greuningen, Malou, et al.
Publicado: (2012)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
por: Yang, Wenli, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Motives for early retirement of self-employed GPs in the Netherlands: a comparison of two time periods
por: Van Greuningen, Malou, et al.
Publicado: (2012)

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
por: van Laar, S.A., et al.
Publicado: (2022)

Differences in sociodemographic, drug use and health characteristics between never, former and current injecting, problematic hard-drug users in the Netherlands
por: Havinga, Petra, et al.
Publicado: (2014)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients
por: Gagliardi, Thomas A, et al.
Publicado: (2022)

P1382: CIRCULATING CAR-T CELLS MONITORING OF KINETICS AND EXHAUSTION MARKERS AS PREDICTIVE FACTORS IN B-CELL MALIGNANCIES
por: Sierro Martínez, Belén, et al.
Publicado: (2023)

Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in the Netherlands based on medication dispensing data
por: Hoefsloot, W, et al.
Publicado: (2023)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
por: Mei, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pb8j1nfkfbap60e0vpjvqep5vn